<?xml version="1.0" encoding="UTF-8"?>
<p id="Par27" class="p">While erythromycin and clindamycin were indicated as alternative therapy to GBS IAP, there has been increasing resistance of GBS to these drugs and in the United States of America (USA), clindamycin and erythromycin resistance have been recorded at 13–20% and 25–35% respectively [
 <xref ref-type="bibr" rid="CR2" class="xref">2</xref>]. Across the world, resistance has been estimated at 14.5–70% and 8.2–70% for erythromycin and clindamycin respectively [
 <xref ref-type="bibr" rid="CR1" class="xref">1</xref>]. The CDC guidelines removed erythromycin as a second line prophylactic antibiotic in women with penicillin allergy due to the high resistance of GBS to it while clindamycin is still acceptable but only after susceptibility testing [
 <xref ref-type="bibr" rid="CR7" class="xref">7</xref>].
</p>
